[关键词]
[摘要]
葡萄膜炎是一种病因及发病机制复杂、治疗棘手、易反复发作的临床常见难治性致盲性眼病，目前认为与自身免疫性炎症反应密切相关。肿瘤坏死因子-α(TNF-α)在葡萄膜炎发生发展中起关键促炎因子作用，阿达木单抗(ADA)是针对TNF-α的全人源化重组免疫γ球蛋白单克隆抗体，可特异性结合TNF-α并阻断其与受体(TNFR-1、TNFR-2)结合而发挥生物学效应。本文就ADA治疗非感染性葡萄膜炎的作用机制、有效性及安全性等临床研究进展进行综述。
[Key word]
[Abstract]
Uveitis is a clinically common refractory blinding eye disease with complicated etiology and pathogenesis that is difficult to treat and prone to recurrence. It is currently considered to be closely associated autoimmune inflammatory response. Tumor necrosis factor-α(TNF-α)acts as a key pro-inflammatory factor in development and progression of uveitis. Adalimumab(ADA)is a fully humanized recombinant anti-immunoglobulin monoclonal antibody targeting TNF-α, and exerts its biological effects by specifically binding to TNF-α and blocking its binding to tumor necrosis factor receptors(TNFR-1/TNFR-2). This paper reviews the clinical research progress on the mechanism, efficacy and safety of ADA in the treatment of non-infectious uveitis.
[中图分类号]
[基金项目]
云南省科技厅科技计划项目\〖No.2019FE001(-169)\〗; 云南省“两类”人才培养项目(No.202005AC160021)
